Article Link: FDA Approves Pretomanid for Highly Drug-Resistant Forms of Tuberculosis NEW YORK August 14, 2019 – Pretomanid, a nove...
FDA Approves Eylea (aflibercept) Injection Prefilled Syringe
Article Link: FDA Approves Eylea (aflibercept) Injection Prefilled Syringe TARRYTOWN, N.Y., Aug. 13, 2019 /PRNewswire/ — Regeneron ...
FDA Approves Turalio (pexidartinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumors (TGCT) in Adults
Article Link: FDA Approves Turalio (pexidartinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumors (TGCT) in Adults Today,...
FDA Approves Keytruda (pembrolizumab) for Recurrent Locally Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Article Link: FDA Approves Keytruda (pembrolizumab) for Recurrent Locally Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus ...
FDA Approves Nubeqa (darolutamide) for Men with Non-Metastatic Castration-Resistant Prostate Cancer
Article Link: FDA Approves Nubeqa (darolutamide) for Men with Non-Metastatic Castration-Resistant Prostate Cancer WHIPPANY, N.J., July 30...
FDA Approves Accrufer (ferric maltol) for the Treatment of Iron Deficiency in Adults
Article Link: FDA Approves Accrufer (ferric maltol) for the Treatment of Iron Deficiency in Adults London, UK, 26 July 2019: Shield Thera...
FDA Approves Baqsimi (glucagon) Nasal Powder for the Treatment of Severe Hypoglycemia
Article Link: FDA Approves Baqsimi (glucagon) Nasal Powder for the Treatment of Severe Hypoglycemia July 24, 2019 — The U.S. Food a...
FDA Approves Hadlima (adalimumab-bwwd), a Biosimilar to Humira
Article Link: FDA Approves Hadlima (adalimumab-bwwd), a Biosimilar to Humira INCHEON, Korea – July 24, 2019 – Samsung Bioepis Co., Ltd. t...
FDA Approves Ruxience (rituximab-pvvr), a Biosimilar to Rituxan
Article Link: FDA Approves Ruxience (rituximab-pvvr), a Biosimilar to Rituxan July 23, 2019 – Pfizer Inc. today announced the Unite...
Baxter Announces U.S FDA Approval of Myxredlin, the First and Only Ready-To-Use Insulin for IV Infusion
Article Link: Baxter Announces U.S FDA Approval of Myxredlin, the First and Only Ready-To-Use Insulin for IV Infusion DEERFIELD, Ill. ...
